Boehringer Ingelheim’s Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation Boehringer Ingelheim’s Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation Boehringer Ingelheim’s Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation
FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab* FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab* FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*
Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program. Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program. Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program.
Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison
Boehringer Ingelheim to unveil oncology research at WCLC Boehringer Ingelheim to unveil oncology research at WCLC Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.
Boehringer Ingelheim Animal Health Appoints Randolph Legg to Lead U.S. Commercial Business Boehringer Ingelheim Animal Health Appoints Randolph Legg to Lead U.S. Commercial Business Boehringer Ingelheim Animal Health Appoints Randolph Legg to Lead U.S. Commercial Business
Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017 Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017 Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection) FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection) FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation
Boehringer Ingelheim unveils groundbreaking Research and Development space in St. Joseph, Mo. Boehringer Ingelheim unveils groundbreaking Research and Development space in St. Joseph, Mo. Boehringer Ingelheim unveils groundbreaking Research and Development space in St. Joseph, Mo.
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim Pharmaceuticals, Inc. Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim Pharmaceuticals, Inc. Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim Pharmaceuticals, Inc.
FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD
Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia
Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials
Boehringer Ingelheim Animal Health Joins Coalition Calling for Greater Broadband Access in Rural Areas Boehringer Ingelheim Animal Health Joins Coalition Calling for Greater Broadband Access in Rural Areas Boehringer Ingelheim Animal Health Joins Coalition Calling for Greater Broadband Access in Rural Areas
Boehringer Ingelheim US Veterinary Scholars Program Profiles | Boehringer Ingelheim US Boehringer Ingelheim US Veterinary Scholars Program Profiles | Boehringer Ingelheim US Click here to find out more how the Boehringer Ingelheim veterinary scholars program has helped 3,500 people over 30 years. Read five of their stories here.
ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US American Thoracic Society Announces that Boehringer Ingelheim is the first donor of its COVID‐19 Crisis Fund
Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office
Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis
FDA Approves Boehringer Ingelheim’s STIOLTO™ RESPIMAT® Inhalation Spray as Once-Daily Maintenance Treatment for COPD FDA Approves Boehringer Ingelheim’s STIOLTO™ RESPIMAT® Inhalation Spray as Once-Daily Maintenance Treatment for COPD FDA Approves Boehringer Ingelheim’s STIOLTO™ RESPIMAT® Inhalation Spray as Once-Daily Maintenance Treatment for COPD